Information Provided By:
Fly News Breaks for August 28, 2015
UNFI, SSNC, PBY, NVO, IRG, DNKN, DPZ, DGII, CPGX, CERU, APLE, ANIK, AVG
Aug 28, 2015 | 10:03 EDT
Today's noteworthy initiations include: AVG Technologies (AVG) initiated with a Buy at Dougherty... Anika Therapeutics (ANIK) initiated with an Equal-Weight at First Analysis... Apple Hospitality REIT (APLE) initiated with an Outperform at Baird... Cerulean (CERU) initiated with a Buy at Roth Capital... Columbia Pipeline Group (CPGX) initiated with a Market Perform at Wells Fargo... Digi International (DGII) initiated with a Buy at Lake Street... Domino's Pizza (DPZ) initiated with a Buy at Maxim... Dunkin' Brands (DNKN) initiated with a Buy at Maxim... Ignite Restaurant (IRG) initiated with a Buy at Sidoti... Novo Nordisk (NVO) initiated with a Market Perform at Leerink... Pep Boys (PBY) initiated with a Buy at Northcoast... SS&C (SSNC) initiated with a Neutral at Macquarie... United Natural Foods (UNFI) initiated with a Sell at Pivotal Research.
News For AVG;ANIK;APLE;CERU;CPGX;DGII;DPZ;DNKN;IRG;NVO;PBY;SSNC;UNFI From the Last 2 Days
NVO
Mar 26, 2024 | 07:08 EDT
JPMorgan estimates Amgen (AMGN) without its obesity pipeline is worth $240-$250 per share and that the market is assigning $30-$40 per share of value to Maritide. While the competitive bar for Maritide is high and moving higher based on Novo Nordisk's (NVO) recent pipeline updates, the obesity market is also "unprecedented in terms of size," the analyst tells investors in a research note. The firm estimates peak sales for Maritide of $6B, equating to mid-single-digit share within the incretin space. JPMorgan believes this supports a value roughly in-line with what is reflected in Amgen's current share price. It sees a positive risk/reward scenario given the recent pullback but maintains a Neutral rating on the name with a $290 price target. The firm says Amgen is viewed as the best positioned name beyond Eli Lilly (LLY) and Novo to have a role in the obesity space.